| Q33358496 | Actual body weight for determining doses of chemotherapy in obese cancer patients: evaluation of treatment tolerability |
| Q36580547 | Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation |
| Q36631641 | Animal models of skin disease for drug discovery. |
| Q43746121 | Association between weight gain during adjuvant chemotherapy for early-stage breast cancer and survival outcomes |
| Q35848771 | Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia |
| Q35949084 | Cardiac toxicity of high-dose chemotherapy |
| Q45298196 | Chemotherapy dosing in achondroplastic dwarfism: a case report and review of literature. |
| Q35814842 | Chemotherapy-Related Amenorrhea and Menopause in Young Chinese Breast Cancer Patients: Analysis on Incidence, Risk Factors and Serum Hormone Profiles |
| Q81527118 | Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger |
| Q36289384 | Clinical pharmacokinetics of cyclophosphamide |
| Q70146495 | Clinical pharmacokinetics of cyclophosphamide |
| Q46026321 | Detection of single-strand breaks and base damage in DNA of blood cells from leukaemia patients receiving chemo- and radiotherapy |
| Q38164666 | Dosing considerations for obese patients receiving cancer chemotherapeutic agents |
| Q57905159 | Dosing of thioTEPA for myeloablative therapy |
| Q33184074 | Dosing strategies for anticancer drugs: the good, the bad and body-surface area |
| Q37940887 | Drug dosing and monitoring in obese patients undergoing allogenic stem cell transplantation |
| Q43587855 | Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area |
| Q38037349 | Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: a systematic review |
| Q34053786 | Effects of obesity on pharmacokinetics implications for drug therapy |
| Q34459665 | Evaluation of chemotherapy-induced severe myelosuppression incidence in obese patients with capped dosing |
| Q43567644 | Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11. |
| Q38107969 | Hormone-related pharmacokinetic variations associated with anti-breast cancer drugs |
| Q37019414 | Ifosfamide pharmacokinetics |
| Q35139846 | Impact of obesity in the setting of high-dose chemotherapy |
| Q42202383 | Impact of pretransplant body mass index on the clinical outcome after allogeneic hematopoietic SCT. |
| Q40748711 | Is body composition an important variable in the pharmacokinetics of anticancer drugs? A review and suggestions for further research |
| Q33901287 | Metabolism and pharmacokinetics of oxazaphosphorines |
| Q35886589 | Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study |
| Q37617204 | Nutritional factors in ovarian cancer survival |
| Q74554552 | Obesity and autologous stem cell transplantation in acute myeloid leukemia |
| Q26863606 | Obesity in cancer survival |
| Q44927215 | Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight |
| Q28383479 | Perceived Stress Levels, Chemotherapy, Radiation Treatment and Tumor Characteristics Are Associated with a Persistent Increased Frequency of Somatic Chromosomal Instability in Women Diagnosed with Breast Cancer: A One Year Longitudinal Study |
| Q36441485 | Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management |
| Q37594760 | Pharmacology of morphine in obese patients: clinical implications |
| Q94544633 | Population Pharmacokinetic, Pharmacogenetic, and Pharmacodynamic Analysis of Cyclophosphamide in Ethiopian Breast Cancer Patients |
| Q83200302 | Population pharmacokinetics of cyclophosphamide in patients with thalassemia major undergoing HSCT |
| Q80001979 | Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity |
| Q77761715 | Practical treatment guide for dose individualisation in cancer chemotherapy |
| Q37034836 | Prognostic value of chemotherapy-induced leukopenia in small-cell lung cancer |
| Q69361463 | Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution |
| Q64969762 | Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. |
| Q35852614 | Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. |
| Q21142666 | The average body surface area of adult cancer patients in the UK: a multicentre retrospective study |
| Q102388853 | Towards integration of 64Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer |
| Q38056012 | Trimming the fat: obesity and hematopoietic cell transplantation |